Clinical and Translational Oncology

, Volume 11, Issue 9, pp 604–608 | Cite as

Clinical experience with biweekly CHOP plus rituximab chemoimmunotherapy for the treatment of aggressive B-cell non-Hodgkin lymphoma

  • David Aguiar BujandaEmail author
  • José Aguiar Morales
  • Uriel Bohn Sarmiento
  • Salvador Saura Grau
  • Carlos Rodríguez Franco
Research Articles



The results of CHOP-21 (cyclophosphamide, doxorubicin, vincristine and prednisone given every 21 days) for the treatment of aggressive B-cell lymphoma have recently been improved by the addition of rituximab and by increasing the dose density. R-CHOP-14 combines these two approaches.

Patients and methods

We present our experience with R-CHOP-14 in a retrospective single-centre review of 50 patients consecutively treated for aggressive B-cell lymphoma.


The median age was 59 years and 48% of patients were >60 years. Stage III–IV was present in 62% of the patients and international prognostic index was high-to-intermediate risk or high risk in 32% of the patients. Toxicity was mainly haematological, with grade 3–4 neutropenia observed in 32% and febrile neutropenia in 18%. Other relevant toxicities were peripheral neuropathy in 45% (grade 3 in 4%) and cardiac dysfunction grade 3 in 7.5%. After therapy, 82% of the patients achieved complete response or unproved complete response. With a median follow-up of 30 months, 3-year event-free survival and overall survival were 67% and 82% respectively.


In our experience the combination of R-CHOP-14 is highly effective in patients with aggressive B-cell lymphoma. However special attention must be paid to the control of early and late toxicities.


Aggressive B-cell lymphoma CHOP Dose-dense chemotherapy Rituximab 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gordon LI, Harrington D, Andersen J et al (1992) Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin’s lymphoma. N Engl J Med 327:1342–1349PubMedCrossRefGoogle Scholar
  2. 2.
    Fisher RI, Gaynor ER, Dahlberg S et al (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non Hodgkin’s lymphoma. N Engl J Med 328:1002–1006PubMedCrossRefGoogle Scholar
  3. 3.
    Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242PubMedCrossRefGoogle Scholar
  4. 4.
    Habermann TM, Weller EA, Morrison VA et al (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121–3127PubMedCrossRefGoogle Scholar
  5. 5.
    Pfreundschuh M, Trumper L, Osterborg A et al (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379–391PubMedCrossRefGoogle Scholar
  6. 6.
    Pfreundschuh M, Trümper L, Kloess M et al (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHLB1 trial of the DSHNHL. Blood 104:626–633PubMedCrossRefGoogle Scholar
  7. 7.
    Pfreundschuh M, Trümper L, Kloess M et al (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104:634–641PubMedCrossRefGoogle Scholar
  8. 8.
    Jaffe ES, Harris NL, Stein H, Vardiman JW (2001) World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer, Lyon, FranceGoogle Scholar
  9. 9.
    The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329:987–994CrossRefGoogle Scholar
  10. 10.
    Hryniuk W, Bush H (1984) The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2:1281–1288PubMedGoogle Scholar
  11. 11.
    Cancer Therapy Evaluation Program (1998) Common toxicity criteria, version 2.0. National Cancer Institute, Bethesda, MDGoogle Scholar
  12. 12.
    Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an International Workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol 17:1244–1253PubMedGoogle Scholar
  13. 13.
    Halaas JH, Moskowitz CH, Horwitz S et al (2005) RCHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy. Leuk Lymph 46:541–547CrossRefGoogle Scholar
  14. 14.
    Brusamolino E, Rusconi C, Montalbetti L et al (2006) Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large-B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica 91:496–502PubMedGoogle Scholar
  15. 15.
    Rueda A, Sabin P, Rifa J et al (2008) R-CHOP-14 in patients with diffuse large B-cell lymphoma younger than 70 years: a multicentre, prospective study. Hematol Oncol 26:27–32PubMedCrossRefGoogle Scholar
  16. 16.
    Rigacci L, Nassi L, Alterini R et al (2006) Dosedense CHOP plus rituximab (R-CHOP-14) for the treatment of elderly patients with high-risk diffuse large B-cell lymphoma: a pilot study. Acta Haematol 115:22–27PubMedCrossRefGoogle Scholar
  17. 17.
    Pfreundschuh M, Schubert J, Ziepert M et al (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 9:105–116PubMedCrossRefGoogle Scholar
  18. 18.
    Pfreundschuh M, Zeynalova S, Poeschel V et al (2008) Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL) after dose-dense rituximab: Results of the DENSE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). J Clin Oncol 26[15 Suppl]:abstr 8508Google Scholar

Copyright information

© Feseo 2009

Authors and Affiliations

  • David Aguiar Bujanda
    • 1
    Email author
  • José Aguiar Morales
    • 1
  • Uriel Bohn Sarmiento
    • 1
  • Salvador Saura Grau
    • 1
  • Carlos Rodríguez Franco
    • 1
  1. 1.Servicio de Oncología MédicaHospital Universitario de Gran Canaria Dr. NegrínLas Palmas de Gran CanariaSpain

Personalised recommendations